Mirum Pharmaceuticals, Inc. (MIRM): who owns it and who trades it
As of Nov 16, 2026, MIRM insiders reported 61 open-market sales worth $44.7M and 1 purchase worth $9M in the last 12 months, with 61% of the sale value made under pre-set 10b5-1 plans. The largest seller was Christopher Peetz (CEO), with $18.1M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Mirum Pharmaceuticals
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns MIRM
323 funds and institutions reported MIRM shares worth $8.4B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Frazier Life Sciences Management, L.P. with 12.6%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 7.68M | 12.59% | $899M | No change |
| Jupiter Topco LLC | 5.91M | 9.69% | $692M | – |
| BlackRock, Inc. | 4.39M | 7.20% | $514M | +14% |
| FMR LLC (Fidelity) | 3.67M | 6.02% | $430M | +87% |
| T. Rowe Price Associates | 2.66M | 4.35% | $311M | +55% |
| Vanguard Portfolio Management LLC | 2.38M | 3.90% | $278M | +66% |
| Vanguard Capital Management LLC | 2.25M | 3.70% | $264M | -7% |
| State Street Corp | 2.17M | 3.56% | $254M | +12% |
| William Blair Investment Management, LLC | 1.40M | 2.30% | $164M | +318% |
| Geode Capital Management, LLC | 1.39M | 2.29% | $163M | +11% |
| Invesco Ltd. | 1.36M | 2.24% | $160M | +378% |
| Wellington Management Group LLP | 1.31M | 2.15% | $153M | -2% |
| Eventide Asset Management, LLC | 1.25M | 2.05% | $146M | -11% |
| Tang Capital Management LLC | 1.24M | 2.03% | $145M | No change |
| Capital World Investors | 1.15M | 1.89% | $135M | +59% |
| Franklin Resources Inc | 1.15M | 1.89% | $135M | +61% |
| Novo Holdings A/s | 1.12M | 1.84% | $132M | -15% |
| TCG Crossover Management, LLC | 1.06M | 1.74% | $124M | No change |
| Bvf Inc | 1.06M | 1.73% | $124M | -33% |
| Polar Capital Holdings Plc | 845,524 | 1.39% | $99M | +198% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, MIRM insiders reported $9M of open-market purchases and $44.7M of sales. 61% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | Laura Brege | Director | Sale | 10,907 | $94.05 | $1M | Form 4 |
| Nov 11, 2026 | Laura Brege | Director | Sale | 3,260 | $94.74 | $309K | Form 4 |
| Nov 4, 2026 | Christopher Peetz | CEO | Sale plan | 20,000 | $90.00 | $1.8M | Form 4 |
| Sep 14, 2026 | Eric Bjerkholt | CFO | Sale | 9,943 | $98.37 | $978K | Form 4 |
| Sep 2, 2026 | Jolanda Howe | Vice president | Sale plan | 658 | $100.00 | $65.8K | Form 4 |
| Sep 1, 2026 | Christopher Peetz | CEO | Sale plan | 8,312 | $98.08 | $815K | Form 4 |
| Sep 1, 2026 | Christopher Peetz | CEO | Sale plan | 21,688 | $98.91 | $2.1M | Form 4 |
| Aug 18, 2026 | Jolanda Howe | Vice president | Sale | 40,000 | $100.00 | $4M | Form 4 |
| Aug 11, 2026 | Eric Bjerkholt | CFO | Sale plan | 6,001 | $99.90 | $599K | Form 4 |
| Aug 10, 2026 | Christopher Peetz | CEO | Sale plan | 6,017 | $99.25 | $597K | Form 4 |
| Aug 10, 2026 | Christopher Peetz | CEO | Sale plan | 11,683 | $98.51 | $1.2M | Form 4 |
| Aug 10, 2026 | Christopher Peetz | CEO | Sale plan | 2,300 | $100.14 | $230K | Form 4 |
| Aug 3, 2026 | Jolanda Howe | Vice president | Sale plan | 1,840 | $105.29 | $194K | Form 4 |
| Jul 6, 2026 | Christopher Peetz | CEO | Sale plan | 12,134 | $121.65 | $1.5M | Form 4 |
| Jul 6, 2026 | Christopher Peetz | CEO | Sale plan | 4,181 | $122.34 | $512K | Form 4 |
| Jul 6, 2026 | Christopher Peetz | CEO | Sale plan | 1,710 | $124.79 | $213K | Form 4 |
| Jul 6, 2026 | Christopher Peetz | CEO | Sale plan | 1,975 | $123.74 | $244K | Form 4 |
| Jul 6, 2026 | Eric Bjerkholt | CFO | Sale plan | 300 | $124.94 | $37.5K | Form 4 |
| Jul 6, 2026 | Eric Bjerkholt | CFO | Sale plan | 528 | $123.84 | $65.4K | Form 4 |
| Jul 6, 2026 | Eric Bjerkholt | CFO | Sale plan | 1,048 | $122.43 | $128K | Form 4 |
| Jul 6, 2026 | Eric Bjerkholt | CFO | Sale plan | 3,124 | $121.67 | $380K | Form 4 |
| Jul 1, 2026 | Jolanda Howe | Vice president | Sale plan | 2,721 | $120.00 | $327K | Form 4 |
| Jun 17, 2026 | Jolanda Howe | Vice president | Sale plan | 2,594 | $101.95 | $264K | Form 4 |
| Jun 8, 2026 | Eric Bjerkholt | CFO | Sale plan | 1,175 | $93.95 | $110K | Form 4 |
| Jun 8, 2026 | Eric Bjerkholt | CFO | Sale plan | 2,258 | $92.84 | $210K | Form 4 |
| Jun 8, 2026 | Eric Bjerkholt | CFO | Sale plan | 1,567 | $95.12 | $149K | Form 4 |
| Jun 1, 2026 | Christopher Peetz | CEO | Sale plan | 883 | $99.66 | $88K | Form 4 |
| Jun 1, 2026 | Christopher Peetz | CEO | Sale plan | 1,021 | $98.20 | $100K | Form 4 |
| Jun 1, 2026 | Christopher Peetz | CEO | Sale plan | 1,973 | $97.56 | $192K | Form 4 |
| Jun 1, 2026 | Christopher Peetz | CEO | Sale plan | 6,926 | $96.15 | $666K | Form 4 |
| Jun 1, 2026 | Christopher Peetz | CEO | Sale plan | 16,595 | $95.34 | $1.6M | Form 4 |
| Jun 1, 2026 | Christopher Peetz | CEO | Sale plan | 2,602 | $94.64 | $246K | Form 4 |
| Jun 1, 2026 | Saira Ramasastry | Director | Sale | 3,977 | $100.00 | $398K | Form 4 |
| May 15, 2026 | Saira Ramasastry | Director | Sale plan | 2,000 | $109.47 | $219K | Form 4 |
| Apr 15, 2026 | Saira Ramasastry | Director | Sale plan | 2,000 | $96.90 | $194K | Form 4 |
| Mar 16, 2026 | Saira Ramasastry | Director | Sale plan | 2,000 | $90.76 | $182K | Form 4 |
| Mar 16, 2026 | Eric Bjerkholt | CFO | Sale | 7,287 | $91.98 | $670K | Form 4 |
| Mar 16, 2026 | Peter Radovich | President | Sale | 16,515 | $91.98 | $1.5M | Form 4 |
| Mar 16, 2026 | Jolanda Howe | Vice president | Sale | 4,732 | $91.98 | $435K | Form 4 |
| Mar 16, 2026 | Christopher Peetz | CEO | Sale | 40,985 | $91.98 | $3.8M | Form 4 |
| Feb 13, 2026 | Saira Ramasastry | Director | Sale plan | 2,000 | $102.09 | $204K | Form 4 |
| Feb 2, 2026 | Peter Radovich | President | Sale | 2,631 | $103.30 | $272K | Form 4 |
| Feb 2, 2026 | Christopher Peetz | CEO | Sale | 9,108 | $103.30 | $941K | Form 4 |
| Feb 2, 2026 | Jolanda Howe | Vice president | Sale | 968 | $103.30 | $100K | Form 4 |
| Jan 26, 2026 | Eric Bjerkholt | CFO | Sale | 1,053 | $96.19 | $101K | Form 4 |
| Jan 26, 2026 | Peter Radovich | President | Sale | 3,143 | $96.19 | $302K | Form 4 |
| Jan 26, 2026 | Jolanda Howe | Vice president | Sale | 842 | $96.19 | $81K | Form 4 |
| Jan 26, 2026 | Christopher Peetz | CEO | Sale | 6,831 | $96.19 | $657K | Form 4 |
| Jan 23, 2026 | Patrick J Heron | Director | Purchase | 131,425 | $68.48 | $9M | Form 4 |
| Jan 22, 2026 | Jolanda Howe | Vice president | Sale | 926 | $93.33 | $86.4K | Form 4 |
| Jan 22, 2026 | Joanne Quan | CHIEF MEDICAL OFFICER | Sale | 1,822 | $93.33 | $170K | Form 4 |
| Jan 22, 2026 | Eric Bjerkholt | CFO | Sale | 1,421 | $93.33 | $133K | Form 4 |
| Jan 22, 2026 | Peter Radovich | President | Sale | 2,382 | $93.33 | $222K | Form 4 |
| Jan 22, 2026 | Christopher Peetz | CEO | Sale | 7,098 | $93.33 | $662K | Form 4 |
| Jan 20, 2026 | Joanne Quan | CHIEF MEDICAL OFFICER | Sale | 6,911 | $90.27 | $624K | Form 4 |
| Jan 15, 2026 | Saira Ramasastry | Director | Sale plan | 2,000 | $90.99 | $182K | Form 4 |
| Dec 22, 2025 | Saira Ramasastry | Director | Sale plan | 5,000 | $80.00 | $400K | Form 4 |
| Dec 19, 2025 | Michael G Grey | Director | Sale plan | 50,000 | $78.00 | $3.9M | Form 4 |
| Dec 18, 2025 | Saira Ramasastry | Director | Sale plan | 1,000 | $69.46 | $69.5K | Form 4 |
| Dec 18, 2025 | Saira Ramasastry | Director | Sale plan | 1,000 | $70.00 | $70K | Form 4 |
| Dec 1, 2025 | Michael G Grey | Director | Sale plan | 50,000 | $74.00 | $3.7M | Form 4 |
| Nov 21, 2025 | Michael G Grey | Director | Sale plan | 50,000 | $70.00 | $3.5M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Christopher Peetz | CHIEF EXECUTIVE OFFICER, Director | – | $18.1M | Nov 4, 2026 |
| Michael G Grey | Director | – | $11.1M | Dec 19, 2025 |
| Patrick J Heron | Director | $9M | – | Jan 23, 2026 |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | – | $5.6M | Sep 2, 2026 |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | – | $3.6M | Sep 14, 2026 |
| Peter Radovich | PRESIDENT AND COO | – | $2.3M | Mar 16, 2026 |
| Saira Ramasastry | Director | – | $1.9M | Jun 1, 2026 |
| Laura Brege | Director | – | $1.3M | Nov 11, 2026 |
| Joanne Quan | CHIEF MEDICAL OFFICER | – | $794K | Jan 22, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MIRM short interest
Moderate short interest. 10.0% of MIRM shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 20%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 6.52M MIRM shares were sold short, 10.0% of the shares outstanding, down 2.1% from the report before. At the average daily volume of 551,116 shares, buying them all back would take about 11.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 6.52M | 9.99% | -2% | 551,116 | 11.8 |
| Oct 15, 2026 | 6.66M | 10.26% | -5% | 912,849 | 7.3 |
| Sep 30, 2026 | 6.99M | 10.76% | +11% | 910,920 | 7.7 |
| Sep 15, 2026 | 6.28M | 9.67% | +2% | 523,889 | 12.0 |
| Aug 31, 2026 | 6.17M | 9.51% | -5% | 467,192 | 13.2 |
| Aug 14, 2026 | 6.49M | 9.99% | -5% | 892,852 | 7.3 |
| Jul 31, 2026 | 6.82M | 10.51% | -6% | 566,260 | 12.1 |
| Jul 15, 2026 | 7.27M | 11.93% | -3% | 686,482 | 10.6 |
| Jun 30, 2026 | 7.48M | 12.27% | +8% | 1.49M | 5.0 |
| Jun 15, 2026 | 6.91M | 11.33% | +5% | 614,943 | 11.2 |
| May 29, 2026 | 6.56M | 10.76% | -20% | 828,272 | 7.9 |
| May 15, 2026 | 8.20M | 13.44% | -3% | 1.70M | 4.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Mirum Pharmaceuticals company events
Mirum Pharmaceuticals filed 19 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026AnnouncementAnnouncement that Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at American Association for the Study of Liver Diseases On November 10, 2026, Mirum Pharmaceuticals, Inc. announced that the primary endpoint was met in the Phase 3 AZURE-4 study… Filing
- Nov 3, 2026ResultsReleased financial results. Filing
- Oct 26, 2026AnnouncementAnnouncement of Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva On October 26, 2026, Mirum Pharmaceuticals, Inc. announced positive results from Cohort 2 of the pivotal… Filing
- Oct 13, 2026AnnouncementMirum Pharmaceuticals, Inc. announced topline results from the Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older with ultra-rare cholestatic liver diseases, including biliary atresia. Filing
- Sep 28, 2026AnnouncementMirum Pharmaceuticals, Inc. and Incyte Corporation announced that the U.S. Food and Drug Administration approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans… Filing
- Sep 8, 2026LeadershipMirum Pharmaceuticals, Inc. announced that, on September 2, 2026, the Company’s Board of Directors appointed Rob Myers, M.D., to succeed Joanne Quan, M.D., as the Company’s Chief Medical Officer, effective upon Dr. Myers’ beginning employment with the Company, which employment is expected to begin… Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jun 18, 2026VoteReported shareholder vote results. Filing
- May 18, 2026AgreementMirum Pharmaceuticals, Inc. issued $690.0 million of its 0.00% Convertible Senior Notes due 2032, which includes the full exercise of the initial purchasers’ option to purchase up to an additional $90.0 million of Notes. Filing
- May 6, 2026ResultsReleased financial results. Filing
- May 4, 2026AnnouncementMirum Pharmaceuticals, Inc. announced the primary endpoint was met in the VISTAS Phase 2b study evaluating volixibat, an investigational oral ileal bile acid transporter inhibitor, in patients with primary sclerosing cholangitis. Filing
- Apr 27, 2026AnnouncementMirum Pharmaceuticals, Inc. announced the primary endpoint was met in the Phase 2b portion of the AZURE-1 study evaluating brelovitug, an investigational monoclonal antibody designed to bind hepatitis B surface antigen (HBsAg), for the treatment of chronic hepatitis delta virus (HDV). Filing
- Feb 25, 2026ResultsReleased financial results. Filing
- Jan 26, 2026DealMirum Pharmaceuticals, Inc. completed the previously announced acquisition of Bluejay Therapeutics, Inc., a Delaware corporation, contemplated by the Agreement and Plan of Merger and Reorganization, dated December 6, 2025, by and among the Company, Bjork Merger Sub I, Inc., a Delaware corporation… Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 19, 2025AnnouncementIn November 2025, Mirum Pharmaceuticals, Inc. announced that it received a Paragraph IV Certification Notice Letter from Sandoz, Inc., providing notification to the Company that Sandoz has submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration, seeking approval of a… Filing
- Dec 19, 2025AgreementMirum Pharmaceuticals, Inc. entered into a subscription agreement with entities associated with TCG Crossover Management, LLC, an institutional investor, pursuant to which the PIPE Investors have agreed, subject to the terms and conditions of the Subscription Agreement, to purchase immediately… Filing
- Dec 8, 2025AgreementMirum Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger and Reorganization with Bjork Merger Sub I, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company, Bjork Merger Sub II, LLC, a Delaware limited liability company and a direct wholly owned subsidiary… Filing
- Nov 17, 2025AnnouncementMirum Pharmaceuticals, Inc. received a Paragraph IV Certification Notice Letter from Sandoz, Inc. providing notification to the Company that Sandoz has submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to manufacture, use or sell a generic… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Mirum Pharmaceuticals financials
Famous investors that hold MIRM
5 of the 50 well-known investors we track reported holding MIRM in their latest 13F filing. The largest position is Steve Cohen's, worth $46.7M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 546,005 | $46.7M | 0.1% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 361,385 | $30.9M | 0.0% | -18% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 196,199 | $16.8M | 0.0% | +138% |
| Israel Englander · Millennium Management | Q3 2026 | 153,266 | $13.1M | 0.0% | +59% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 98,219 | $8.4M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named MIRM in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 8.5% |
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 8.5% |
Questions about Mirum Pharmaceuticals, Inc. (MIRM) stock
Who owns the most MIRM stock?
The largest reported owner of Mirum Pharmaceuticals, Inc. (MIRM) is Frazier Life Sciences Management, L.P., with 12.6% of the company. In total, 323 funds and institutions reported holding MIRM at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are MIRM insiders buying or selling?
In the last 12 months, MIRM insiders reported 1 open-market purchase worth $9M and 61 sales worth $44.7M. The latest trade was on Nov 11, 2026. See every trade.
What is the short interest in MIRM?
As of Oct 30, 2026, 6.52M MIRM shares were sold short, 10.0% of the shares outstanding, down 2.1% from the report before. At the average daily volume of 551,116 shares, buying them all back would take about 11.8 trading days (days to cover). See the history.
Which famous investors hold MIRM?
5 of the 50 well-known investors we track reported MIRM in their latest 13F filing, including Steve Cohen, Jim Simons, Ken Fisher. The largest position is worth $46.7M. See all holders.
Executive pay
Mirum Pharmaceuticals's chief executive was paid a total of $10.4M for the year ended Dec 31, 2025, up 58% from $6.6M the year before. In the last 12 months, Mirum Pharmaceuticals's executives and directors bought $9M of stock on the open market and sold $44.7M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.